SE397090B - Forfarande for framstellning av hydroxipyrimidiner - Google Patents

Forfarande for framstellning av hydroxipyrimidiner

Info

Publication number
SE397090B
SE397090B SE7505279A SE7505279A SE397090B SE 397090 B SE397090 B SE 397090B SE 7505279 A SE7505279 A SE 7505279A SE 7505279 A SE7505279 A SE 7505279A SE 397090 B SE397090 B SE 397090B
Authority
SE
Sweden
Prior art keywords
hydroxipyrimidines
procedure
preparation
Prior art date
Application number
SE7505279A
Other languages
English (en)
Other versions
SE7505279L (sv
Inventor
C A Lipinski
J G Stam
G G Deangelis
H-J E Hess
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SE7505279L publication Critical patent/SE7505279L/sv
Publication of SE397090B publication Critical patent/SE397090B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
SE7505279A 1971-10-29 1975-05-06 Forfarande for framstellning av hydroxipyrimidiner SE397090B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19400671A 1971-10-29 1971-10-29

Publications (2)

Publication Number Publication Date
SE7505279L SE7505279L (sv) 1975-05-06
SE397090B true SE397090B (sv) 1977-10-17

Family

ID=22715935

Family Applications (2)

Application Number Title Priority Date Filing Date
SE7212358A SE393376B (sv) 1971-10-29 1972-09-25 Forfarande for framstellning av pyrimidinonderivat
SE7505279A SE397090B (sv) 1971-10-29 1975-05-06 Forfarande for framstellning av hydroxipyrimidiner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SE7212358A SE393376B (sv) 1971-10-29 1972-09-25 Forfarande for framstellning av pyrimidinonderivat

Country Status (25)

Country Link
JP (2) JPS5337870B2 (sv)
AR (2) AR198798A1 (sv)
AT (2) AT320656B (sv)
AU (1) AU467600B2 (sv)
BE (1) BE790125A (sv)
CA (1) CA980778A (sv)
CH (2) CH555832A (sv)
DE (3) DE2264657C2 (sv)
DK (1) DK131465B (sv)
EG (1) EG11013A (sv)
ES (2) ES407730A1 (sv)
FI (1) FI55503C (sv)
FR (1) FR2157865B1 (sv)
GB (2) GB1377720A (sv)
IE (1) IE37043B1 (sv)
IL (2) IL40458A (sv)
LU (1) LU66304A1 (sv)
NL (1) NL166470C (sv)
NO (1) NO136574C (sv)
PH (2) PH10129A (sv)
PL (2) PL89852B1 (sv)
SE (2) SE393376B (sv)
SU (2) SU498908A3 (sv)
YU (2) YU35125B (sv)
ZA (1) ZA727362B (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55151912U (sv) * 1979-04-17 1980-11-01
JPS5752409Y2 (sv) * 1979-11-05 1982-11-15
DE3222914A1 (de) * 1982-06-18 1983-12-22 Beiersdorf Ag, 2000 Hamburg Substituierte 5-phenylthio-6-amino-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
JPH0655686B2 (ja) * 1988-08-30 1994-07-27 宇部興産株式会社 ｐ−ブロモフェノキシアセトアルデヒドジアルキルアセタール類の製造方法
JP5113752B2 (ja) 2005-08-22 2013-01-09 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
AU2018250795B2 (en) 2017-04-10 2022-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of adipocytes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913462A (en) * 1959-11-17 Eahl h
GB951432A (en) * 1959-03-17 1964-03-04 Wellcome Found Pyrimidine derivatives and the manufacture thereof

Also Published As

Publication number Publication date
PH11594A (en) 1978-03-31
IE37043L (en) 1973-04-29
IL40458A (en) 1976-05-31
IE37043B1 (en) 1977-04-27
CA980778A (en) 1975-12-30
AT320656B (de) 1975-02-25
FR2157865B1 (sv) 1975-10-31
NL7213959A (sv) 1973-05-02
YU35125B (en) 1980-09-25
PL84634B1 (sv) 1976-04-30
DE2264657A1 (de) 1974-06-20
LU66304A1 (sv) 1973-05-03
GB1377720A (en) 1974-12-18
FI55503B (fi) 1979-04-30
JPS5422995B2 (sv) 1979-08-10
AR196263A1 (es) 1973-12-10
DE2248741B2 (de) 1974-11-14
ES436624A1 (es) 1977-02-01
GB1377308A (en) 1974-12-11
NL166470B (nl) 1981-03-16
SU498908A3 (ru) 1976-01-05
DK131465B (da) 1975-07-21
JPS5337870B2 (sv) 1978-10-12
JPS53116386A (en) 1978-10-11
DE2264374C3 (de) 1981-07-23
SU505362A3 (ru) 1976-02-28
DE2264374A1 (de) 1973-05-24
PH10129A (en) 1976-09-02
EG11013A (en) 1976-11-30
DE2248741C3 (de) 1975-06-26
AR198798A1 (es) 1974-07-24
YU255172A (en) 1980-03-15
ES407730A1 (es) 1976-01-16
CH555832A (fr) 1974-11-15
IL48790A (en) 1976-05-31
YU99179A (en) 1981-08-31
NL166470C (nl) 1981-08-17
NO136574B (sv) 1977-06-20
IL48790A0 (en) 1976-03-31
FR2157865A1 (sv) 1973-06-08
FI55503C (fi) 1979-08-10
DE2264374B2 (de) 1980-08-07
PL89852B1 (sv) 1976-12-31
AU467600B2 (en) 1975-12-04
DK131465C (sv) 1975-12-08
CH549579A (fr) 1974-05-31
JPS4852780A (sv) 1973-07-24
DE2248741A1 (de) 1973-05-03
YU36295B (en) 1982-06-18
IL40458A0 (en) 1972-11-28
ZA727362B (en) 1973-11-28
NO136574C (no) 1977-09-28
SE393376B (sv) 1977-05-09
BE790125A (fr) 1973-04-16
AU4722872A (en) 1974-04-04
SE7505279L (sv) 1975-05-06
DE2264657C2 (de) 1982-09-16
AT321308B (de) 1975-03-25

Similar Documents

Publication Publication Date Title
SE392269B (sv) Forfarande for framstellning av vissa indanyloxitetrazoler
SE398877B (sv) Forfarande for framstellning av 14-hydroxi-morfinanderivat
SE411755B (sv) Forfarande for framstellning av n-substituerade 1-aminometylindaner
SE400292B (sv) Forfarande for framstellning av benshydryl-3-karbamoyloximetyl-7-tienylacetamido-7-metoxidecefalosporanat
NO147916C (no) Fremgangsmaate for fremstilling av 3-metylen-cefalosporin-forbindelser.
SE390633B (sv) Forfarande for framstellning av ethambutol
SE417200B (sv) Forfarande for framstellning av 2-nitro-5-imidazolaldehydderivat
SE400764B (sv) Forfarande for framstellning av substituerade 3-hydroximetylisokinoliner
SE393615B (sv) Forfarande for framstellning av 6-metyl-8 beta-ureidometyl-ergolener
SE405478B (sv) Forfarande for framstellning av alfa-sulfoacylcefalosporiner
SE384686B (sv) Forfarande for framstellning av linkomycinderivat
SE391332B (sv) Forfarande for framstellning av en fenyletanolamin
SE412756B (sv) Alternativa forfarande for framstellning av 2-(aminofenylimino)-3-aza-1-tia-cykloalkaner
SE397090B (sv) Forfarande for framstellning av hydroxipyrimidiner
SE408177B (sv) Forfarande for framstellning av 4-hydroximetyl-1-ftalazonderivat
SE380815B (sv) Forfarande for framstellning av transparenta sampolyamider
SE387936B (sv) Forfarande for framstellning av substituerade metoxiaminer
SE382985B (sv) Forfarande for framstellning av oxazoler
SE380520B (sv) Forfarande for framstellning av 1-cinnamylidenamino-3-bensylidenaminoguanidin
SE398123B (sv) Forfarande for framstellning av metoximetylestern av hetacillin
SE386897B (sv) Forfarande for framstellning av n-acyl-(piperazinoetyl)-pyrazoler
SE392902B (sv) Forfarande for framstellning av fenylimidazolidinoner
SE405730B (sv) Forfarande for framstellning av kinazolinderivat
SE397350B (sv) Forfarande for framstellning av tieno-diazepinderivat
SE407061B (sv) Forfarande for framstellning av bensylpyrimidiner